ArticleBMC infectious diseases2017
Rifampicin resistance in mycobacterium tuberculosis patients using GeneXpert at Livingstone Central Hospital for the year 2015: a cross sectional explorative study.
Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Antimicrobial resistance from a One Health perspective in Zambia: a systematic review.Antimicrobial resistance and infection control · 2023Pooled it
- Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children.The Cochrane database of systematic reviews · 2022Pooled it
- Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children.The Cochrane database of systematic reviews · 2020Pooled it
- Association of D516V, H526Y, and S531L rpoB gene polymorphisms and risk factors with rifampicin resistance in Mycobacterium tuberculosis isolates from pulmonary TB patients in Northwest Amhara, Ethiopia: cross-sectional study.BMC infectious diseases · 2025Article
- Pre-treatment loss to follow-up and associated factors among drug-resistant tuberculosis patients diagnosed in Wakiso district, central Uganda.BMC infectious diseases · 2025Article
- Article
- Trend of pulmonary tuberculosis and rifampicin-resistance among tuberculosis presumptive patients in Central Tigray, Ethiopia; 2018 -2023: a six-year retrospective study.Tropical diseases, travel medicine and vaccines · 2024Article
- The clinical profile and outcomes of drug resistant tuberculosis in Central Province of Zambia.BMC infectious diseases · 2024Review
- First and Second-Line Anti-Tuberculosis Drug-Resistance Patterns in Pulmonary Tuberculosis Patients in Zambia.Antibiotics (Basel, Switzerland) · 2023Article
- Rifampicin resistantSAGE open medicine · 2023Article
- Drug Resistance ofJournal of immunology research · 2023Article
- Prevalence of rifampicin resistant tuberculosis among pulmonary tuberculosis patients In Enugu, Nigeria.African health sciences · 2022Article
- Detection ofTuberculosis research and treatment · 2022Article
- Clinical spectrum of active tuberculosis in patients with systemic lupus erythematosus.Rheumatology international · 2021Article
- Prevalence of rifampicin resistance tuberculosis among HIV/TB coinfected patients in Benue State, Nigeria.The Pan African medical journal · 2021Article
- A pilot study on the genetic diversity ofJournal of clinical tuberculosis and other mycobacterial diseases · 2020Article
- Trends ofTropical diseases, travel medicine and vaccines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince the recent introduction of GeneXepert for the detection of Tuberculosis (TB) drug resistance mutations in both primary resistance and acquired resistance in Zambia, little has been documented in literature on the issue of rifampicin resistance especially in the face of a high National TB burden. The study aimed to determine the prevalence of rifampicin resistance in tuberculosis patients at Livingstone Central Hospital for the year 2015.
methodsThis was a cross sectional study conducted at Livingstone Central Hospital where we reviewed 152 records (from January 1, 2015 to 31st December, 2015) involving patients who presented with clinically suspected TB or documented TB, whose samples were sent to the laboratory for GeneXpert Mycobacterium tuberculosis/rifampicin testing. Statistical evaluations used a one-sample test of proportion and Fisher's exact test.
resultsThe age of participants ranged from 8 months to 73 years old (median = 34). Of the participants with complete data on gender, 99 (66%) and 52 (34%) were males and females respectively. The TB co-infection with HIV prevalence was 98.3% (p < 0.001). Prevalence of rifampicin resistance was 5.9% and there was no statistical significant difference between being male or female (p = 0.721).
conclusionWe were able to show from our study, evidence of rifampicin resistance at Livingstone Central Hospital. Hence, there was need for further in-depth research and appropriate interventions (i.e close follow-up and patient care for drug resistance positive patients).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.